Sosei Group Corporation Release: Planned Development Of Inhaled Triple Therapy QVM149 For Asthma
TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (“Sosei”) (TOKYO:4565) confirms the plan to be announced later today by Novartis at a “Meet Novartis Management” investor event in Boston, USA to develop a new inhaled triple therapy for patients with moderate to severe asthma uncontrolled by standard ICS/LABA medication.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.